Biopharma AI
By
Can ProFound Therapeutics and Novartis’ $750M AI-Driven Cardiovascular Pact Redefine Drug Discovery from the Human Proteome?
Key Highlights AI Meets Proteomics: A New Paradigm in Cardiovascular DiscoveryIn a bold step toward AI-enabled medicine, ProFound…
Is Insilico’s AI-Driven UAE University Alliance the Catalyst for a New Generation of Biotech Talent?
Key Highlights Academic Meets AI Innovation in UAEInsilico Medicine, a leader in generative AI for drug discovery, has…
Is Sanofi’s $632M AI Bet on Formation Bio the Next Big Immunology Breakthrough?
French pharma giant doubles down on AI-native R&D with gusacitinib licensing deal targeting new inflammatory indication Key Takeaways…
Accelerating Drug Discovery with Artificial Intelligence: Strategic Insights from Pharma’s Biggest AI Alliances
Executive SummaryThe convergence of artificial intelligence (AI) and drug discovery is a strategic imperative. Pharmaceutical giants including Sanofi,…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
